CASE REPORT

Case Report: β-thalassemia major on the East African coast

[version 1; peer review: 2 approved]

Alexander W. Macharia1, George Mochamah1, Johnstone Makale1, Thad Howard2, Neema Mturi1, Peter Olupot-Olupot3,4, Anna Färnert5, Russell E. Ware2, Thomas N. Williams1,6

1Epidemiology and Demography Department, KEMRI/Wellcome Trust Kilifi, Kilifi, 254, Kenya
2Division of Hematology, Cincinnati Children’s Hospital Medical Center, OH, USA
3Mbale Clinical Research Institute, Mbale, Uganda
4Busitema University Faculty of Health Sciences, Mbale, Uganda
5Karolinska Institute, Stockholm, Sweden
6Institute for Global Health Innovation, Imperial College, London, UK

Abstract

Background: β-thalassemia is rare in sub-Saharan Africa and to our knowledge there has been no case of homozygous β-thalassemia major reported from this region. In a recent cohort study, we identified four β-thalassemia mutations among 83 heterozygous carriers in Kilifi, Kenya. One of the mutations identified was a rare β-globin gene initiation codon mutation (ATGACG) (rs33941849). Here we present a patient with β-thalassemia major resulting from this mutation, only the second homozygous patient to have been reported.

Methods: The female patient presented to Kilifi County Hospital aged two years with a one week left sided abdominal swelling. Clinical, hematological and genetic information were collected at admission and follow-up.

Results: Admission bloods revealed marked anemia, with a hemoglobin (Hb) value of 6.6 g/dL and a low mean corpuscular volume of 64 fl. High performance liquid chromatography (HPLC) revealed the absence of HbA0 and elevated levels of HbF, suggesting a diagnosis of β-thalassemia major. Sequencing revealed that the child was homozygous for the rs33941849 initiation codon mutation.

Conclusions: We hope that this study will create awareness regarding the presence of β-thalassemia as a potential public health problem in the East Africa region and will prompt the development of local guidelines regarding the diagnosis and management of this condition.

Keywords

β-thalassemia major, rs33941849, East Africa, HbA2, sequencing
Corresponding author: Alexander W. Macharia (amacharia@kemri-wellcome.org)

Author roles: Macharia AW: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Mochamah G: Conceptualization, Formal Analysis, Investigation, Writing – Review & Editing; Makale J: Data Curation, Formal Analysis, Methodology, Project Administration; Howard T: Data Curation, Formal Analysis, Investigation, Methodology; Mturi N: Investigation, Methodology, Resources; Olupot-Olupot P: Validation, Writing – Review & Editing; Färnert A: Validation, Writing – Review & Editing; Ware RE: Methodology, Visualization, Writing – Review & Editing; Williams TN: Funding Acquisition, Methodology, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome [202800; a Senior Research Fellowship award to TNW]. AWM is supported through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769/Z/10/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. This paper is published with permission from the Director of the Kenya Medical Research Institute.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Macharia AW et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Macharia AW, Mochamah G, Makale J et al. Case Report: β-thalassemia major on the East African coast [version 1; peer review: 2 approved] Wellcome Open Research 2022, 7:188 https://doi.org/10.12688/wellcomeopenres.17907.1

First published: 13 Jul 2022, 7:188 https://doi.org/10.12688/wellcomeopenres.17907.1
Introduction

β-thalassemia is rare in most of Africa, with the exception of North Africa where the prevalence, causal pathogenic variants and disease outcomes have all been well described previously (Hamamy & Al-Allawi, 2013). We recently reported elevated levels of HbA2 suggestive of β-thalassemia, in a small proportion of children participating in a cohort study conducted in Kilifi county on the coast of Kenya (Macharia et al., 2019). We subsequently sequenced samples from the same children and found that 0.6% were carriers of one of four different β-thalassemia pathogenic variants: the β⁰-thalassemia variants CD22 (GAA→TAA) (rs33959855), initiation codon (ATG→ACG) (rs33941849) and IVS-3′ end del 25bp (rs193922563) and the β⁺-thalassemia variant IVS-I-110 (G→A) (rs35004220). Whereas the mutations observed in North Africa resemble those found in Middle Eastern countries, those identified in Kilifi were a mixture of mutations reported from Asia and the Middle East. To the best of our knowledge, no cases of β-thalassemia major – a condition in which both HBB genes are affected by a β⁺-thalassemia mutation to result in the complete loss of normal β⁺-globin production - have yet been reported from the East Africa region. Here, we describe what is, to the best of our knowledge, the first case of β⁺-thalassemia major to be recognised from within this region.

Ethics

Written informed consent was provided by the parents of the study participant. Ethical approval for the study was granted by the Kenya Medical Research Institute Ethical Review Committee in Nairobi, Kenya (Number: SCC3891).

Patient report

The child, a two-and-a-half-year-old female, presented to Kilifi County Hospital in Kenya, with a one-week history of left sided abdominal swelling. No previous hospital admissions were reported. Clinical history suggested delayed developmental milestones; specifically, she was unable to walk without support. The child was the fourth born of five siblings, all of whom were alive and well as were both of her parents. Both her parents were of Mijikenda ethnolinguistic ancestry and no recent genetic admixture was apparent from the clinical history. On physical examination, the child was pale but had no signs of clinical jaundice. Her vital signs were essentially normal with the exception of a fever measured at 38.8°C per axilla. Fronto-maxillary skull bossing was apparent. Her abdomen was distended, soft and non-tender, massive splenomegaly being detected at 8cm below the costal margin. She was severely malnourished with a weight of 8.8 kg, a height of 78.5 cm, a height for age z-score (HAZ) of -3.79, a weight for age z-score (WAZ) of -3.20 and a weight for height z-score (WHZ) of -1.23. Further examination was essentially normal. The timeline of events is given in Table 1.

A full hemogram revealed marked anemia (Hb 6.6 g/dL), a low mean corpuscular volume (MCV) of 64 fL, a low mean corpuscular hemoglobin (MCH) of 19.4 pg, and a raised total white blood cell (WBC) count of 49.6 x 10⁹/L which were predominantly lymphocytes. Her platelet count was normal at 321 x 10⁹/L and her creatinine mildly elevated at 32 µmol/l. Blood cultures and tests for malaria were negative. A peripheral blood film revealed nucleated red blood cells (RBCs), microcytes, dacrocyes, acanthocytes, giant platelets and a marked lymphocytosis (Table 2).

The child was admitted to the general pediatric ward with a working diagnosis of iron deficiency anemia, potentially complicated by bacterial sepsis, and with a differential diagnosis of sickle cell anemia. She was treated empirically with iron and folic acid supplementation for her anemia and with intravenous penicillin and gentamicin to cover sepsis. She was also prescribed malaria prophylaxis with proguanil pending analysis for sickle cell anemia by high-performance liquid chromatography.

Table 1. Timeline of events.

| Age at presentation | Symptoms | Diagnostic Testing | Interventions |
|---------------------|----------|--------------------|---------------|
| 2 years 6 months    | • Delayed developmental milestones  
                     • Left sided abdominal swelling  
                     • 8 prior transfusions (other hospital)  
                     • Low grade fever  
                     • Bissing of the skull  
                     • Massive splenomegaly  
                     • Malnutrition | • HPLC analysis; absence of HbA and elevated Hbf (>80% of total Hb)  
                     • Sequenced her HBB gene region, which revealed she was homozygous for the initiation codon (ATG→ACG) mutation (rs33941849)  
                     • Full haemogram; hb 6.6gm/dl | • Admission  
                     • Treated for suspected sepsis |
| 3 years 11 months   | • Cough  
                     • Fever  
                     • Splenomegaly  
                     • Malnutrition  
                     • Transfusion dependent anaemia | • PCR for the α⁺-² deletional form of α-thalassemia was negative  
                     • Repeat HPLC analysis revealed the continued absence of HbA, Hbf (>80% of total Hb) and HbA2 at 5% | • Began regular monthly blood transfusions  
                     • Referred for surgical splenectomy |
Her fever subsided within two days of admission, at which point she was discharged home on oral amoxicillin, with follow-up planned for the following week.

The results of her HPLC analysis, received after discharge from hospital, revealed the absence of normal adult hemoglobin (HbA), normal levels of HbA2 at 2.5% and elevated levels of fetal hemoglobin (HbF) (>80% of total Hb) that eluted in adjacent peaks A1b (16%) and LA1c/cHb1 (76.5%) (Figure 1). The complete absence of HbA suggested a diagnosis of β0-thalassemia major. We therefore sequenced her HBB gene region as described in detail previously.

---

**Table 2. Complete blood count and peripheral blood film from the child with β-thalassemia.**

| Parameter          | First admission | Second Admission |
|--------------------|-----------------|------------------|
| HbA2 (%)           | 2.5             | 5.0              |
| HbF (%)            | >80%            | >80%             |
| WBC count (x10³/μl)| 49.6            | 20.5             |
| RBC count (x10⁶/μl)| 3.38            | 1.10             |
| Hb (g/dl)          | 6.6             | 2.2              |
| HCT (%)            | 21.5            | 6.2              |
| MCV (FL)           | 64              | 56               |
| MCH (pg)           | 19.4            | 20.1             |
| Platelets (x10⁹/L) | 321             | 330              |

**Peripheral Blood Film**

Leucocytosis, lymphocytosis, Nucleated red blood cells, dacrocytes, anisocytosis and giant platelets

Abbreviations: WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; HCT, hematocrit; MCV, mean cell volume; MCH, mean cell hemoglobin; PBF, peripheral blood film. ‡Age=2.5 years. †Age=3.5 years.

---

**Figure 1.** HPLC chromatograms from study participants with normal hemoglobin A individual (HbAA), homozygous hemoglobin S (HbSS) and homozygous β-thalassemia patient at first admission (age 2.5 years) and at second admission (age 3.5 years).
(Clark & Thein, 2004), which revealed that the child was homozygous for the initiation codon (ATG→ACG) mutation (rs33941849).

Initially lost to follow-up, the child re-presented at the age of three years 11 months with a one-week history of a cough and fever. On examination at that time, her spleen remained grossly enlarged at 10 cm, and she remained malnourished with a HAZ of -4.98, a WAZ of -4.01 and a WHZ of -0.99. Although hemodynamically stable, she was profoundly anemic (Hb 2.2 g/dL) and was therefore transfused and treated with folic acid supplementation and nutritional support. Repeat HPLC analysis revealed the continued absence of HbA together with elevated levels of HbF (>80%) and HbA₂ (at 5%) (Figure 1). PCR for the α⁺-thalassemia depletional form of α-thalassemia was negative.

Discussion
To the best of our knowledge, this is the first case of homozygous β-thalassemia to be reported from the East Africa region. The mutation responsible disrupts the transfer RNA binding site to result in a β⁺ form of the disease. It appears to be rare in other populations: only 45 carriers have been reported in the literature to date, 20 of which were from our recently reported study (Macharia et al., 2020). Other reports of carriers have come from a wide range of countries including Switzerland (Beris et al., 1993), Belgium (Wildmann et al., 1993), Russia (Molchanova et al., 1998), India (Gorakshakar et al., 2018; Gupta et al., 2002) and the former Yugoslavia (Jankovic et al., 1990). The only homozygous case described to date was a male child of Pakistani origin who presented at 10 months of age with a palpable liver and spleen at 7 cm and 3 cm below costal margin, respectively. His Hb was 9.2 g/dL, MCV of 73 fl and MCH of 33 pg. He was also found to be homozygous for the α⁺-thalassemia deletion and to have a Bantu β-globin gene cluster haplotype. He was managed with regular blood transfusions (Khan et al., 2000).

On comparing the current and previously described cases, all had anemia, a low MCV and massive splenomegaly. In our current patient, we also observed elevated levels of HbF and varying levels of HbA₂ at the two points of testing, an observation which is common in β-thalassemia major (Steinberg & Rodgers, 2015). Options for the treatment of this condition in our context are limited. Throughout much of the world, first line management includes the provision of regular, leuco-depleted blood transfusions together with extended antigen typing of transfused blood to reduce the risk of alloimmunization. Iron-chelation is also used to mitigate the risk of iron overload (Steinberg et al., 2009) while more recently, allogeneic hematopoietic cell transplantation (HCT) is also being used as a potentially curative therapy. However, all these strategies are beyond the capacity of our local health-care system. Nevertheless, there is growing evidence to support the use of hydroxyurea, an HbF inducer, in the treatment of transfusion and non-transfusion dependent β-thalassemia (Algiraigri et al., 2017a; Algiraigri et al., 2017b). We will investigate this strategy together with surgical splenectomy if the child returns for further follow-up in the hope that these will reduce the frequency at which transfusions will be required.

Conclusions
We have previously estimated the birth prevalence of β-thalassemia major in our local community at approximately 1 in 100,000 (Macharia et al., 2020). Nevertheless, low awareness of this condition among clinicians and the low availability of diagnostic facilities within the region mean that historically, individuals with β-thalassemia major have probably been misdiagnosed with other conditions such as sickle cell anemia or iron deficiency anemia as was the case with this child. As such, we hope that our case study will raise awareness about the existence and clinical importance of β-thalassemia major as a public health problem within the East Africa region and lead to the development of locally appropriate diagnostic and treatment guidelines.

Data availability
Underlying data
All data underlying the results are available as part of the article and no additional source data are required.

Consent
Written informed consent for publication of their clinical details was obtained from the parents of the patient.

References
Algiraigri AH, Wright NAM, Paolucci EO, et al.: Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis. Pediatr Hematol Oncol. 2017a; 34(8): 435–448. PubMed Abstract | Publisher Full Text

Algiraigri AH, Wright NAM, Paolucci EO, et al.: Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2017b; 10(3): 116–125. PubMed Abstract | Publisher Full Text

Beris P, Darbellay R, Speiser D, et al.: De novo initiation codon mutation (ATG→ACG) of the beta-globin gene causing beta-thalassemia in a Swiss family. Am J Hematol. 1993; 42(3): 248–253. PubMed Abstract | Publisher Full Text

Clark BE, Thein SL: Molecular diagnosis of haemoglobin disorders. Clin Lab Haematol. 2004; 26(3): 159–176. PubMed Abstract | Publisher Full Text

Gorakshakar AC, Breganza PV, Colaco SP, et al.: Rare β- and δ-Globin Gene Mutations in the Pathare Prabhus: Original Inhabitants of Mumbai, India. Hemoglobin. 2018; 42(5–6): 297–301. PubMed Abstract | Publisher Full Text

Gupta A, Hattori Y, Agarwal S: Initiation codon mutation in an Asian Indian family. Am J Hematol. 2002; 71(2): 134–136. PubMed Abstract | Publisher Full Text

Hamamy HA, Al-Allawi NA: Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet. 2013; 4(2): 147–167. PubMed Abstract | Publisher Full Text | Free Full Text
Jankovic L, Efremov GD, Josifovska O, et al.: An initiation codon mutation as a cause of a beta-thalassemia. Hemoglobin. 1990; 14(2): 169–176.

PubMed Abstract | Publisher Full Text

Khan SN, Riazuddin S, Galanello R: Identification of three rare beta-thalassemia mutations in the Pakistani population. Hemoglobin. 2000; 24(1): 15–22.

PubMed Abstract | Publisher Full Text

Macharia AW, Mochamah G, Uyoga S, et al.: β-Thalassemia pathogenic variants in a cohort of children from the East African coast. Mol Genet Genomic Med. 2020; 8(7): e1294.

PubMed Abstract | Publisher Full Text | Free Full Text

Macharia AW, Uyoga S, Ndila C, et al.: The population dynamics of hemoglobins A, A₂, F and S in the context of the hemoglobinopathies HbS and α-thalassemia in Kenyan infants. Haematologica. 2019; 104(5): e184–e186.

PubMed Abstract | Publisher Full Text | Free Full Text

Molchanova TP, Postnikov Yu V, Gu LH, et al.: Historical note: the beta-thalassemia allele in the noble Russian family Lermontov is identified as the ATG-->ACG change in the initiation codon. Hemoglobin. 1998; 22(3): 283–286.

PubMed Abstract | Publisher Full Text

Steinberg MH, Forget BG, Higgs DR, et al.: Disorders of Hemoglobin: Genetics Pathophysiology, and Clinical Management. 2nd edn. Cambridge University Press, Cambridge. 2009.

Reference Source

Steinberg MH, Rodgers GP: HbA₂: biology, clinical relevance and a possible target for ameliorating sickle cell disease. Br J Haematol. 2015; 170(6): 781–787.

PubMed Abstract | Publisher Full Text

Wildmann C, Larondelle Y, Vaerman JL, et al.: An initiation codon mutation as a cause of beta-thalassemia in a Belgian family. Hemoglobin. 1993; 17(1): 19–30.

PubMed Abstract | Publisher Full Text
Open Peer Review

Current Peer Review Status: 🔄 🔄

Version 1

Reviewer Report 04 October 2023

https://doi.org/10.21956/wellcomeopenres.19844.r67871

© 2023 Ropero P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paloma Ropero
Hospital Clínico San Carlos, Madrid, Spain

This work presents the case of a baby with homozygous beta-thalassemia in a region where this had not been previously reported.

The report is interesting because it shows that there could be similar cases and confuse the diagnosis with sickle cell anemia or severe iron deficiency.

This study provides valuable information about β-thalassemia in a region where it is rare and presents a rare clinical case that may help improve the diagnosis and treatment of this condition in the future.

Unfortunately, local conditions hinder the ability to provide optimal treatment.

Do you know if the parents are family? Are they related?

Is the background of the case's history and progression described in sufficient detail? Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes? Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment? Yes

Is the case presented with sufficient detail to be useful for other practitioners? Yes
**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Hemoglobinopathies and thalassemia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.